GELS vs ATXI vs DARE

For growth investors, Daré Bioscience, Inc.

(DARE) is the stronger pick with -99. 7% revenue growth year-over-year, versus -100. 0% for Gelteq Limited Ordinary Shares (GELS). The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Daré Bioscience, Inc.

(DARE) delivered a total return of -82. 4%, compared to -100. 0% for Avenue Therapeutics, Inc. (ATXI). Over 10 years, the gap is even starker: GELS returned -84. 1% versus ATXI's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Avenue Therapeutics, Inc.

(ATXI) is the lower-risk stock at -0. 11β versus Gelteq Limited Ordinary Shares's 1. 16β — meaning GELS is approximately -1159% more volatile than ATXI relative to the S&P 500.

By revenue growth (latest reported year), Daré Bioscience, Inc.

(DARE) is pulling ahead at -99. 7% versus -100. 0% for Gelteq Limited Ordinary Shares (GELS). On earnings-per-share growth, the picture is similar: Gelteq Limited Ordinary Shares grew EPS 100. 0% year-over-year, compared to 88. 4% for Daré Bioscience, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Avenue Therapeutics, Inc.

(ATXI) is the more profitable company, earning -266. 7% net margin versus -414. 3% for Daré Bioscience, Inc. — meaning it keeps -266. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ATXI leads at -279. 8% versus -2396. 9% for DARE. At the gross margin level — before operating expenses — GELS leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Avenue Therapeutics, Inc.

(ATXI) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0. 11)). Both have compounded well over 10 years (ATXI: -100. 0%, GELS: -84. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.